# Ixovex-1 Single Agent and Combination Therapy

Source: https://onco.cc/trials/nct06549946/  
OnCo record `nct06549946` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab in head and neck squamous cell carcinoma, run by Psivac Ltd, now recruiting.

## Summary

Ixovex-1 Single Agent and Combination Therapy is a phase 1/2 interventional study registered as NCT06549946 by Psivac Ltd, with 18 participants planned, started 2024-12-17 and due to reach its primary completion in 2027-01-30. Interventions recorded: Ixovex-1 and Pembrolizumab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06549946
- Phase: 1/2
- Setting: A Phase I/II Open-label, Clinical Trial of Intratumoural Ixovex-1 as Single Agent Therapy or in Combination With Pembrolizumab in Palpable Solid Tumours
- Sponsor: Psivac Ltd
- Enrolled: 18

## Sources

- ClinicalTrials.gov NCT06549946: https://clinicaltrials.gov/study/NCT06549946

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [IQVIA](https://onco.cc/companies/iqvia/)

---
JSON: https://onco.cc/api/v1/entities/nct06549946.json